AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company provides manifolds, contrast management systems, closed fluid systems, guidewires, disposable transducers, and interventional accessories that help clinicians in the diagnosis and treatment of cardiovascular and peripheral vascular diseases; VenaCure EVLT laser system products to treat superficial venous diseases; Asclera drug for treating uncomplicated spider and reticular veins of the lower extremities; and Sotradecol drugs for treating small uncomplicated varicose veins of the lower extremities. It also offers AngioVac venous drainage system that includes venous drainage cannula for the removal of fresh, soft thrombi, or emboli during extracorporeal bypass; and cardiopulmonary bypass circuit for use in procedures during extracorporeal circulatory support. In addition, the company provides thrombolytic catheters to deliver thrombolytic agents; angiographic products and accessories for use in during peripheral vascular interventional procedures; drainage products, which drain abscesses and other fluid pockets; and micro access sets. Further, it offers peripherally inserted central catheters; ports that are implantable devices for the central venous administration; and dialysis products. Additionally, the company provides microwave ablation products; radiofrequency ablation products for ablating solid cancerous or benign tumors; and NanoKnife ablation systems for the surgical ablation of soft tissues. It sells and markets its products to interventional radiologists, interventional cardiologists, vascular surgeons, urologists, and interventional and surgical oncologists directly, as well as through distributor relationships. The company was founded in 1988 and is headquartered in Latham, New York.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNASDAQ:ANGO
CUSIP03475V10
Phone518-795-1400
Debt
Debt-to-Equity Ratio0.16
Current Ratio2.88
Quick Ratio1.84
Price-To-Earnings
Trailing P/E Ratio30.26
Forward P/E Ratio30.34
P/E Growth1.57
Sales & Book Value
Annual Sales$349.64 million
Price / Sales2.36
Cash Flow$1.4493 per share
Price / Cash15.49
Book Value$14.00 per share
Price / Book1.60
Profitability
EPS (Most Recent Fiscal Year)$0.73
Net Income$5 million
Net Margins0.97%
Return on Equity5.11%
Return on Assets3.81%
Miscellaneous
Employees1,250
Outstanding Shares36,810,000
AngioDynamics (NASDAQ:ANGO) Frequently Asked Questions
What is AngioDynamics' stock symbol?
AngioDynamics trades on the NASDAQ under the ticker symbol "ANGO."
How were AngioDynamics' earnings last quarter?
AngioDynamics, Inc. (NASDAQ:ANGO) posted its quarterly earnings data on Thursday, March, 29th. The medical instruments supplier reported $0.25 EPS for the quarter, topping the Zacks' consensus estimate of $0.20 by $0.05. The medical instruments supplier had revenue of $83.85 million for the quarter, compared to the consensus estimate of $86.13 million. AngioDynamics had a return on equity of 5.11% and a net margin of 0.97%. View AngioDynamics' Earnings History.
When is AngioDynamics' next earnings date?
What price target have analysts set for ANGO?
7 analysts have issued 1-year target prices for AngioDynamics' shares. Their forecasts range from $16.00 to $21.00. On average, they expect AngioDynamics' share price to reach $17.5825 in the next twelve months. View Analyst Ratings for AngioDynamics.
Who are some of AngioDynamics' key competitors?
Some companies that are related to AngioDynamics include Novocure (NVCR), NuVasive (NUVA), Merit Medical Systems (MMSI), Nevro (NVRO), Irhythm Technologies (IRTC), Glaukos (GKOS), Mazor Robotics (MZOR), Luminex (LMNX), Intersect ENT (XENT), Orthofix International (OFIX), Atrion (ATRI), OraSure Technologies (OSUR), Cryolife (CRY), Cardiovascular Systems (CSII) and Tactile Systems Technology (TCMD).
Who are AngioDynamics' key executives?
AngioDynamics' management team includes the folowing people:
- Mr. James C. Clemmer, Pres, CEO & Director (Age 54)
- Mr. Michael C. Greiner, Exec. VP, CFO & Principal Accounting Officer (Age 45)
- Mr. Stephen A. Trowbridge, Sr. VP, Gen. Counsel & Assistant Sec. (Age 44)
- Mr. Chad T. Campbell, Sr. VP & Gen. Mang. of Global Vascular Access (Age 47)
- Mr. Robert A. Simpson, Sr. VP Peripheral Vascular (Age 46)
Has AngioDynamics been receiving favorable news coverage?
News headlines about ANGO stock have trended somewhat positive on Wednesday, according to Accern Sentiment. The research group identifies positive and negative press coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. AngioDynamics earned a media sentiment score of 0.19 on Accern's scale. They also gave news headlines about the medical instruments supplier an impact score of 46.59 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near term.
Who are AngioDynamics' major shareholders?
AngioDynamics' stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (13.87%), Dimensional Fund Advisors LP (8.40%), Wells Fargo & Company MN (3.30%), Fort Washington Investment Advisors Inc. OH (2.79%), JPMorgan Chase & Co. (2.43%) and Segall Bryant & Hamill LLC (1.77%). Company insiders that own AngioDynamics stock include Avista Capital Partners Gp, Ll, David F Burgstahler, James C Clemmer and Jan Stern Reed. View Institutional Ownership Trends for AngioDynamics.
Which major investors are selling AngioDynamics stock?
ANGO stock was sold by a variety of institutional investors in the last quarter, including Systematic Financial Management LP, American Century Companies Inc., Schwab Charles Investment Management Inc., Spark Investment Management LLC, Prudential Financial Inc., California Public Employees Retirement System, Russell Investments Group Ltd. and Lapides Asset Management LLC. View Insider Buying and Selling for AngioDynamics.
Which major investors are buying AngioDynamics stock?
ANGO stock was purchased by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Segall Bryant & Hamill LLC, BlackRock Inc., Heartland Advisors Inc., Millennium Management LLC, Fort Washington Investment Advisors Inc. OH, Wells Fargo & Company MN and Mackay Shields LLC. Company insiders that have bought AngioDynamics stock in the last two years include James C Clemmer and Jan Stern Reed. View Insider Buying and Selling for AngioDynamics.
How do I buy shares of AngioDynamics?
Shares of ANGO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is AngioDynamics' stock price today?
One share of ANGO stock can currently be purchased for approximately $22.45.
How big of a company is AngioDynamics?
AngioDynamics has a market capitalization of $803.44 million and generates $349.64 million in revenue each year. The medical instruments supplier earns $5 million in net income (profit) each year or $0.73 on an earnings per share basis. AngioDynamics employs 1,250 workers across the globe.
How can I contact AngioDynamics?
AngioDynamics' mailing address is 14 PLAZA DRIVE, LATHAM NY, 12110. The medical instruments supplier can be reached via phone at 518-795-1400 or via email at [email protected]
MarketBeat Community Rating for AngioDynamics (ANGO)
MarketBeat's community ratings are surveys of what our community members think about AngioDynamics and other stocks. Vote "Outperform" if you believe ANGO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ANGO will underperform the S&P 500 over the long term. You may vote once every thirty days.
